High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma
(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer
Avasopasem produces significant improvement of severe oral mucositis in head and neck patients
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer
Everolimus after surgery can improve outcomes in those with high-risk kidney cancer
Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma
N-803-BCG combination shows promising results in BCG-unresponsive NMIBC
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients
Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer